Peter J. Reddig

Array ( [id] => 16635302 [patent_doc_number] => 10913797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Anti-PD-1 antibodies and therapeutic uses thereof [patent_app_type] => utility [patent_app_number] => 15/777015 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 14833 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16139033 [patent_doc_number] => 10702570 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Compositions targeting the interaction domain between p27KiP1 and Brk and methods of use thereof to inhibit p27 Y phosphorylation and cdk4 activity [patent_app_type] => utility [patent_app_number] => 15/351904 [patent_app_country] => US [patent_app_date] => 2016-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 59 [patent_no_of_words] => 18938 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15351904 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11513050 [patent_doc_number] => 20170080123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'Method for Preparing Porous Scaffold for Tissue Engineering, Cell Culture and Cell Delivery' [patent_app_type] => utility [patent_app_number] => 15/347595 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6819 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15347595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11749223 [patent_doc_number] => 09707221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Methods of treating cancer patients with farnesyltransferase inhibitors' [patent_app_type] => utility [patent_app_number] => 15/346675 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 71673 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18219191 [patent_doc_number] => 11594135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Methods of CD40 activation and immune checkpoint blockade [patent_app_type] => utility [patent_app_number] => 15/772789 [patent_app_country] => US [patent_app_date] => 2016-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 19966 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956037 [patent_doc_number] => 11059879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Chimeric antigen receptor molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 15/771128 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 57 [patent_no_of_words] => 27397 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 393 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15771128 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17030793 [patent_doc_number] => 11092603 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => Keratin 17 as a prognostic marker for pancreatic cancer [patent_app_type] => utility [patent_app_number] => 15/771754 [patent_app_country] => US [patent_app_date] => 2016-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12688 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15771754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342153 [patent_doc_number] => 20190153049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => ANTI-PLACENTA-CHONDROITIN-SULFATE CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 15/779382 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15779382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11569856 [patent_doc_number] => 20170108500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'FOXC1 ANTIBODIES AND METHODS OF THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/293117 [patent_app_country] => US [patent_app_date] => 2016-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9185 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15293117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419844 [patent_doc_number] => 20170027988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS' [patent_app_type] => utility [patent_app_number] => 15/293011 [patent_app_country] => US [patent_app_date] => 2016-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10138 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15293011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16406758 [patent_doc_number] => 10815301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-27 [patent_title] => Anti-CD30 chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 15/766948 [patent_app_country] => US [patent_app_date] => 2016-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14390 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866176 [patent_doc_number] => 20170233462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Antibody Against Secreted N-Terminal Peptide of GPC3 Present in Blood or C-Terminal Peptide of GPC3' [patent_app_type] => utility [patent_app_number] => 15/288508 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15549 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15288508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490221 [patent_doc_number] => 20180296653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => ANTI-TUMORAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 15/766510 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145437 [patent_doc_number] => 10253077 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers [patent_app_type] => utility [patent_app_number] => 15/281537 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 25 [patent_no_of_words] => 45908 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395219 [patent_doc_number] => 20170015755 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS' [patent_app_type] => utility [patent_app_number] => 15/280586 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 69232 [patent_no_of_claims] => 99 [patent_no_of_ind_claims] => 45 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15280586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13424857 [patent_doc_number] => 20180263971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => COMBINATION OF TOPOISOMERASE-I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/760995 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17593 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15760995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568936 [patent_doc_number] => 20170107580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'GENE EXPRESSION MARKERS FOR PREDICTING OVERALL SURVIVAL IN SUBJECTS TREATED WITH SIPULEUCEL-T' [patent_app_type] => utility [patent_app_number] => 15/268267 [patent_app_country] => US [patent_app_date] => 2016-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12921 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15268267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17393373 [patent_doc_number] => 11242375 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Immune cell compositions and methods of use [patent_app_type] => utility [patent_app_number] => 15/757276 [patent_app_country] => US [patent_app_date] => 2016-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 77 [patent_no_of_words] => 45595 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11758550 [patent_doc_number] => 20170205419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'CYR61 AS A BIOMARKER FOR DIAGNOSIS AND PROGNOSIS OF CANCERS OF EPITHELIAL ORIGIN' [patent_app_type] => utility [patent_app_number] => 15/249829 [patent_app_country] => US [patent_app_date] => 2016-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7911 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15249829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383597 [patent_doc_number] => 20180243340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => COMBINATION THERAPY COMBINING CAR + T CELLS WITH APPROPRIATELY TIMED IMMUNODULATORY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/753662 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15753662 [rel_patent_id] =>[rel_patent_doc_number] =>)